Prospektive Studien von metastasierenden Prostatakarzinomen: 12 Jahre Erfahrung der urologischen Arbeitsgruppe der EORTC

  • F. H. Schröder
  • die urologische Arbeitsgruppe der EORTC
Conference paper

Zusammenfassung

Die urologische Arbeitsgruppe der EORTC hat in der onkologisch-urologischen Forschung über alle Aspekte des Prostatakarzinoms 12 Jahre Erfahrung. Die Gruppe hat insgesamt 5 Phase-II-Studien beendet, ein sechstes Protokoll ist z. Z. in Arbeit. Drei große randomisierte Studien über nicht vorbehandelte metastasierende Prostatakarzinome wurden abgeschlossen, 4 weitere Protokolle werden zur Zeit bearbeitet. Mehr als 1400 Patienten sind hieran beteiligt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Benson RC, Gill GM, Cummings KB (1983) Randomised double blind crossover trial of Diethyl Stilboestrol (DES) and Estramustine Phosphate (EMCYT). The Stage D Prostatic Cancer. Semin Oncol 10 (Suppl 3): 43–45PubMedGoogle Scholar
  2. Byar DP (1980) A review of the Veterans’ Administration Studies of Cancer of the Prostate: the new results concerning treatment of Stage I and II tumours. In: Pavone Macaluso M, Smith PH, Edsmyr S (eds) Bladder tumours and other topics in urological oncology. Plenum, New York London, pp 471–492Google Scholar
  3. De Voogd HJ, Smith PH, Pavone Macaluso M, de Pauw M, Suciu S, and Members of the European Organization for Research on Treatment of Cancer Urological Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307Google Scholar
  4. Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, Akdas A, de Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer 19: 583–588CrossRefGoogle Scholar
  5. Jones WG and members of the EORTC Genitourinary Cancer Cooperative Group (1984) EORTC Phase II Chemotherapy studies in prostate cancer. In: Denis L, Murphy GP, Prout GR, Schröder FH (eds) Controlled clinical trials in urologic oncology. Raven, New York, pp 181–185Google Scholar
  6. Jones WG, Bono AV, Verbaeys A, de Pauw M, Sylvester R, and members of the EORTC Genitourinary Tract Cancer Cooperative Group (1986a) Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genitourinary Group report. World J Urol 4: 176–181Google Scholar
  7. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, Slyvester R, and members of the EORTC Genitourinary Tract Cancer Cooperative Group (1986b) Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4: 182–185Google Scholar
  8. Jones WG, Fossa SD, Bono AV, Klijn JMG, de Pauw M, Sylvester R (1987) European Organization for Research and Treatment of Cancer ( EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 71: 1317–1318PubMedGoogle Scholar
  9. Pavone Macaluso M, Lund F, Mulder JH, Smith PH, de Pauw M, Sylvester R, and the EORTC Urological Group (1980) EORTC protocols in prostatic cancer. Scand J Urol Nephrol (Suppl) 55: 163–168Google Scholar
  10. Pavone Macaluso M, de Pauw M, Suciu S, Sylvester R, de Voogd HJ, Lardennois B, Nasta A, Zolfanelli R, Barasoldo E, and the EORTC Urological Group (1982) Medroxyprogesterone acetate, diethylstilboestrol and cyproterone acetate in the treatment of the prostatic cancer. Interim report of a prospective study of the European Organization for Research on the Treatment of Cancer (EORTC) Genito-urinary Tract Cooperative Group. Excerpta Medica International Series, pp 436–444Google Scholar
  11. Pavone Macaluso M and the EORTC Urological Group (1983) Medroxyprogesterone acetate in the treatment of prostatic cancer: preliminary results of EORTC trial 30761 comparing MPA with Stilbestrol and with Cyproterone Acetate. In: Campio L, Robustelli Della Cua G, Taylor RW (eds) Role of medroxyprogesterone in endocrine related tumors. Raven, New York, pp 183–190Google Scholar
  12. Pavone Macaluso M, de Voogd HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R (1986) Diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624–631Google Scholar
  13. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42: 283–288PubMedCrossRefGoogle Scholar
  14. Robinson MRG, Hetherington J (1986) The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer? World J Urol 4: 171–175CrossRefGoogle Scholar
  15. Schröder FH, and the EORTC Urological Group (1984) Treatment of prostatic cancer: EORTC experience–preliminary results of prostatic carcinoma trials. Prostate 5: 193–198Google Scholar
  16. Smith PH (1980) Medical management of prostatic cancer. Some current questions. Eur Urol 6: 65–68PubMedGoogle Scholar
  17. Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M, Sylvester R (1986) A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 136: 619–623PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • F. H. Schröder
  • die urologische Arbeitsgruppe der EORTC

There are no affiliations available

Personalised recommendations